Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTWNL74)

• DTT Name: V-set and immunoglobulin domain-containing protein 9 (TIGIT) DTT Info
• Gene Name: TIGIT

Molecule-Related Drug & Molecule List

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AB154	DMUES7Y	Non-small-cell lung cancer	2C25	Phase 3	[1]
Ociperlimab	DMEDSVJ	Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
GSK4428859	DMIOIU8	Aggressive cancer	2A00-2F9Z	Phase 2	[3]
Rilvegostomig	DMDWCM2	Non-small-cell lung cancer	2C25	Phase 1/2	[4]
ASP8374	DMA71OL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
COM902	DMR6T8L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
M6223	DM6J085	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
SEA-TGT	DM7GUH3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]

References

• [1] Clinical pipeline report, company report or official report of Arcus Biosciences.
• [2] Clinical pipeline report, company report or official report of BeiGene.
• [3] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [4] ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26.
• [7] ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Seagen.